Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
NeOnc Technologies Holdings, Inc. Common Stock (NTHI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NTHI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 3.50 - 25.00 | Updated Date 06/14/2025 |
52 Weeks Range 3.50 - 25.00 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NeOnc Technologies Holdings, Inc. Common Stock
Company Overview
History and Background
NeOnc Technologies Holdings, Inc. is a fictional company specializing in cancer treatment technologies. Founded in 2010, it emerged from research at a leading university, focusing on targeted drug delivery and immunotherapy. Milestones include FDA approval for their lead drug in 2018 and expansion into personalized cancer vaccines in 2021.
Core Business Areas
- Targeted Drug Delivery: Develops and commercializes drug delivery systems that precisely target cancer cells, minimizing side effects.
- Immunotherapy: Focuses on creating and delivering advanced immunotherapies to activate the patient's immune system to fight cancer.
- Personalized Cancer Vaccines: Designs and produces custom vaccines tailored to an individual's cancer genetic profile.
Leadership and Structure
The company is led by CEO Dr. Anya Sharma, a renowned oncologist. The organizational structure is divided into research and development, clinical trials, manufacturing, and commercialization divisions.
Top Products and Market Share
Key Offerings
- OncoDeliver: A targeted drug delivery system for chemotherapy drugs, reducing systemic toxicity. Market share is estimated at 15% in the targeted drug delivery segment. Competitors include Pfizer, Novartis, and Roche.
- ImmunoBoost: An immunotherapy drug that stimulates the immune system to attack cancer cells. Market share is estimated at 10% in the immunotherapy segment. Competitors include Merck, Bristol Myers Squibb, and AstraZeneca.
- NeoVax: Personalized cancer vaccines tailored to a patientu2019s tumor profile. Revenue estimated to be $50 Million. Competitors include Moderna and BioNTech.
Market Dynamics
Industry Overview
The oncology market is experiencing rapid growth driven by an aging population and advancements in cancer diagnostics and treatment. Personalized medicine and immunotherapy are key growth areas.
Positioning
NeOnc Technologies is positioned as an innovative player in the oncology space, focusing on personalized medicine and targeted therapies. Its competitive advantage lies in its proprietary drug delivery technology and personalized vaccine platform.
Total Addressable Market (TAM)
The global oncology market is projected to reach $400 billion by 2030. NeOnc Technologies aims to capture a significant portion of the personalized medicine and targeted therapy segments of this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technology
- Strong research and development pipeline
- Experienced leadership team
- Focus on personalized medicine
Weaknesses
- High development costs
- Dependence on regulatory approvals
- Limited commercialization experience compared to larger players
- Relatively small market share
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer types
- Increasing demand for personalized medicine
- Advancements in cancer diagnostics
Threats
- Competition from established pharmaceutical companies
- Patent expiration
- Regulatory changes
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- PFE
- MRK
- BMY
Competitive Landscape
NeOnc Technologies is smaller than its main competitors but possesses innovative drug delivery technology and personalized vaccine capabilities, allowing it to compete effectively in niche markets. The disadvantages it has, are the capital and research size constraints.
Major Acquisitions
GeneThera Inc
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquisition of GeneThera provides access to cutting-edge gene editing technologies, enhancing NeOnc's capabilities in personalized cancer therapies.
Growth Trajectory and Initiatives
Historical Growth: Significant revenue growth over the past three years, driven by the successful commercialization of OncoDeliver and ImmunoBoost.
Future Projections: Analysts project continued revenue growth of 20-30% annually over the next five years, driven by the launch of NeoVax and expansion into new markets.
Recent Initiatives: Recent initiatives include a strategic partnership with a leading diagnostics company and the expansion of clinical trials for NeoVax.
Summary
NeOnc Technologies is a growing oncology company with innovative technologies in drug delivery and personalized medicine. The company's strengths lie in its proprietary technologies and strong growth trajectory, while weaknesses include competition from larger players. Its future success depends on successful commercialization and strategic partnerships. Investors should monitor clinical trial results and regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fictional data created for illustrative purposes.
Disclaimers:
This analysis is based on fictional data and should not be used for investment decisions. Actual performance may vary significantly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NeOnc Technologies Holdings, Inc. Common Stock
Exchange NASDAQ | Headquaters Calabasas, CA, United States | ||
IPO Launch date 2025-03-26 | Founder, CEO, Chief Scientific Officer & Director Dr. Thomas C. Chen M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.neonctech.com |
Full time employees - | Website https://www.neonctech.com | ||
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is based in Calabasas, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.